Loading
Psoriatic Arthritis / Tirzepatide / Overweight Or Obesity · Phase 4 Trial
ClinicalTrials.gov · September 8, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 4 clinical trial registry record describing a planned 12-month study of tirzepatide added to ixekizumab in patients with active psoriatic arthritis and overweight/obesity. No results are posted; the study is currently recruiting. The reader should note that this is a design and enrollment record only, with no efficacy or safety data available.
Phase 4, Interventional, Single Group, Open label, Treatment purpose. Psoriatic Arthritis, Overweight or Obesity; age from 18 Years. Intervention: Tirzepatide. n = 200. 55 sites: United States, Puerto Rico.
This is a Phase 4 clinical trial registry record describing a planned 12-month study of tirzepatide added to ixekizumab in patients with active psoriatic arthritis and overweight/obesity. No results are posted; the study is currently recruiting. The reader should note that this is a design and enrollment record only, with no efficacy or safety data available.
This is a registry record with no reported outcomes or results; efficacy and safety data are not yet available.
No clinical impact can be determined from a registry record with no reported results. Once results are published, this trial may inform the role of tirzepatide as an add-on to ixekizumab in obese or overweight patients with PsA seeking concurrent weight loss and disease control.
This is a Phase 4 registry record with no reported results; it describes a planned interventional study in active recruitment with estimated enrollment of 200 participants and dual primary outcomes at 12 months.
As stated by the source record.
Quoted from the source exactly as published.
No clinical impact can be determined from a registry record with no reported results. Once results are published, this trial may inform the role of tirzepatide as an add-on to ixekizumab in obese or overweight patients with PsA seeking concurrent weight loss and disease control.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06864026). This is a study registration, not published results. Lead sponsor: Eli Lilly and Company. Recruitment status: RECRUITING. Phase: PHASE4. Study type: INTERVENTIONAL. Enrollment: 200 participants (ESTIMATED). Conditions: Psoriatic Arthritis, Overweight or Obesity. Interventions: DRUG: Tirzepatide. Primary outcome measures: Percentage of Participants Achieving Normalized Functioning Health Assessment Questionnaire - Disability Index (HAQ-DI) ≤0.5 at 12 Months of Therapy , 12 Months; Percentage of Participants Achieving at Least a 10% Weight Loss at 12 Months of Therapy , 12 Months. Brief summary: The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with active PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.